Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


Delayed Quote. Delayed  - 07/29 10:00:00 pm
289.93 USD   +0.31%
07/22DJGEORGE SCANGOS : Biogen CEO Scangos to Step Down -- WSJ
07/21 Joy Global and Biogen climb; Intel and Union Pacific slide
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
07/22DJGEORGE SCANGOS : Biogen CEO Scangos to Step Down -- WSJ
07/21 BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
07/21 Joy Global and Biogen climb; Intel and Union Pacific slide
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook--Update
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook
07/21 BIOGEN : rises after 2nd-quarter results surpass forecasts
07/21 BIOGEN INC. : Results of Operations and Financial Condition (form 8-K)
07/21 BIOGEN : Reports Second Quarter 2016 Revenues of $2.9 Billion
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/30DJMERCK : Earnings Watch -- WSJ
07/30 BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07/28 Roche's hemophilia candidate emicizumab shows encouraging results in early-st..
07/28 Quarter 2 Earnings Heading In The Wrong Direction - Week 2 Continued
07/27 BIOTECH DAILY DIGEST : Gilead's Thud, Tobira Gets A Shout-Out, Spotlight On Adva..
07/25 BIOTECH FORUM DAILY DIGEST : Will Biotech Finally Break Out? All Eyes On Gilead,..
07/25 Is Biotech Finally Ready To Move Higher?
Financials ($)
Sales 2016 11 478 M
EBIT 2016 5 947 M
Net income 2016 4 022 M
Finance 2016 1 458 M
Yield 2016 -
P/E ratio 2016 15,85
P/E ratio 2017 14,75
EV / Sales 2016 5,41x
EV / Sales 2017 5,28x
Capitalization 63 530 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 333 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-5.36%63 530
ABBVIE INC11.80%107 118
MERCK KGAA10.26%14 264
KYOWA HAKKO KIRIN CO L..-5.35%10 181
More Results